Skip to main content
. 2022 Jan 15;3(1):121–128. doi: 10.1002/jha2.359

FIGURE 1.

FIGURE 1

(A) Overall survival (OS) of the entire cohort of patients from daratumumab starting therapy. (B) Progression‐free survival (PFS) of the entire cohort of patients from daratumumab starting therapy. (C) OS of the entire cohort of patients from daratumumab starting therapy stratified according to different scheme of therapy. No statistical difference was found (p = .447)